Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation

Bioorg Med Chem. 2019 Feb 15;27(4):630-643. doi: 10.1016/j.bmc.2019.01.003. Epub 2019 Jan 4.

Abstract

It is well known that opioid analgesics produce side effects including tolerance and constipation. Since neuropeptide FF (NPFF) receptor antagonists reversed opioid-induced hyperalgesia and analgesic tolerance, the present work was performed to synthetize two branched peptidomimetics, EKR and RKE, containing the opioid peptide endomorphin-2 (EM-2) and the NPFF receptor antagonist RF9. Our data obtained from the in vitro cyclic adenosine monophosphate experiment demonstrated that EKR functioned as a mixed mu-, delta-opioid receptors agonist and NPFF1 receptor antagonist/NPFF2 receptor partial agonist, whereas RKE acted as a multi-functional peptidomimetic with the mu-opioid agonism and the NPFF1 antagonism/NPFF2 partial agonism. Furthermore, EKR and RKE completely blocked the NPFF2 receptor-mediated neurite outgrowth of Neuro 2A cells. In vivo antinociception studies found that supraspinal administration of EKR and RKE dose-dependently produced potent antinociception via the mu-opioid receptor in the tail-flick test. In carrageenan inflammatory pain model, spinal administration of EKR and RKE induced dose-related analgesia, which was significantly reduced by the opioid antagonist naloxone and the NPFF antagonist RF9. Notably, compared with morphine, intracerebroventricular repeated administration of EKR and RKE maintained prolonged antinociceptive effectiveness. In addition, at the antinociceptive doses, these two branched peptidomimetics did not significantly inhibit gastrointestinal transit. Taken together, the present work suggest that EKR and RKE behave as multi-functional ligands with the opioid agonism and the NPFF1 antagonism/NPFF2 partial agonism, and produce prolonged antinociception with limited side effects. Moreover, our results imply that EKR and RKE might be interesting pharmacological tools for further investigating the biological function of the NPFF and opioid systems.

Keywords: Antinociception; Branched peptidomimetics; Constipation; Endomorphin-2; RF9; Tolerance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / chemical synthesis
  • Analgesics, Opioid / pharmacology*
  • Analgesics, Opioid / therapeutic use
  • Animals
  • Cell Line, Tumor
  • Drug Discovery*
  • Drug Partial Agonism
  • Gastrointestinal Transit / drug effects
  • HEK293 Cells
  • Humans
  • Hyperalgesia / drug therapy
  • Male
  • Mice
  • Morphine / pharmacology
  • Naloxone / pharmacology
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Neuronal Outgrowth / drug effects
  • Peptidomimetics / chemical synthesis
  • Peptidomimetics / pharmacology*
  • Peptidomimetics / therapeutic use
  • Receptors, Neuropeptide / agonists
  • Receptors, Neuropeptide / antagonists & inhibitors
  • Receptors, Opioid, delta / metabolism
  • Receptors, Opioid, mu / metabolism

Substances

  • Analgesics, Opioid
  • Peptidomimetics
  • Receptors, Neuropeptide
  • Receptors, Opioid, delta
  • Receptors, Opioid, mu
  • neuropeptide FF receptor
  • Naloxone
  • norbinaltorphimine
  • Naltrexone
  • Morphine
  • naltrindole